Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma-Reference-Cited by-同舟云学术

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

Published:2008-09 Issue:3 Volume:53 Page:267-277
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:

Author:

Marquard L,Gjerdrum L M,Christensen Ib J,Jensen P B,Sehested M,Ralfkiaer E

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2008.03109.x/fullpdf

Reference69 articles.

1. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer;Willemze;Blood,1997

2. WHO-EORTC classification for cutaneous lymphomas;Willemze;Blood,2005

3. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients;Fink-Puches;Blood,2002

4. UVB in the management of early stage mycosis fungoides;Pavlotsky;J. Eur. Acad. Dermatol. Venereol.,2006

5. Management of the primary cutaneous lymphomas;Prince;Australas. J. Dermatol.,2003

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays;Life Sciences;2024-02

2. Histone deacetylase 6: at the interface of cancer and neurodegeneration;Epigenomics;2023-11

3. HDAC inhibitors: Promising agents for leukemia treatment;Biochemical and Biophysical Research Communications;2023-11

4. Recent advancement of HDAC inhibitors against breast cancer;Medical Oncology;2023-06-09

5. Epigenetics and cutaneous neoplasms: from mechanism to therapy;Epigenomics;2023-02